πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12098385

Gene therapy strategy to restore cardiac electrical and structural function in arrhythmoge

The Regents of the University of California Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12098138

Substituted pyridinyl azetidinone derivatives for use in treating cancer and other disease

The Board of Regents of the University of Texas System Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12098144

Piperazine indazole glucocorticoid receptor antagonists

Corcept Therapeutics Incorporated Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097183

Pharmaceutical composition for treating migraine

Tonix Medicines, Inc. Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12098116

Crystalline prostacyclin (IP) receptor agonist and uses thereof

United Therapeutics Corporation Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097306

Conformal coating of biological surfaces

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097185

Compositions comprising ciprofloxacin and celecoxib

NEUROSENSE THERAPEUTICS LTD. Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097188

Compositions and methods for the treatment of macular degeneration

Aldeyra Therapeutics, Inc. Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12096754

Non-human animals having a humanized lymphocyte-activation gene 3

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097192

Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid rece

Corcept Therapeutics Incorporated Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097261

CDK2 degraders and uses thereof

Kymera Therapeutics, Inc. Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097213

Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation thera

The Board of Regents of the University of Texas System Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12098141

Bicyclic indazole glucocorticoid receptor antagonists

Corcept Therapeutics Incorporated Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097223

Mesenchymal stromal cells and uses related thereto

Astellas Institute for Regenerative Medicine Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097290

Membrane encapsulated nanoparticles and method of use

The Regents of the University of California Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097230

Method and composition for treating post operative conditions

Bright Green Corporation Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097291

Thermostable vaccine compositions and methods of preparing same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097262

mTORC1 inhibitors

The Regents of the University of California Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097196

Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097198

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097199

Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097210

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097263

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Dyne Therapeutics, Inc. Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097219

Single-domain antibodies against CLL1 and constructs thereof

Legend Biotech Ireland Limited Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted